PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study
Year: 2026
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: Valentina Santo, Nikhil Mankuzhy, Kristi Beshiri, Lingzhi Hong, Emanuele C. Mingo, Sagal Pannu, Federica Pecci, Edoardo Garbo, Joao V. Alessi, Eleonora Gariazzo, Leonardo Brunetti, Ayesha Aijaz, Elyse Rose Lopez, Samuel Black, Jamie E. Chaft, Adam J. Schoenfeld, Lynette M. Sholl, Abdul Rafeh Naqash, Alessio Cortellini, Natalie Vokes, Mihaela Aldea, Narek Shaverdian, Biagio Ricciuti
Institutions: Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, The University of Texas MD Anderson Cancer Center, Università Campus Bio-Medico, Campus Bio Medico University Hospital, OU Health Stephenson Cancer Center, Brigham and Women's Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7167273480
Cites:
Cited by:
Related to: